semaglutide trial adolescents obesity 2022 adolescent Two‐year effect of semaglutide 2.4 mg on control of GLP-1 prescribing among teens with
Description
Remaining on lower doses substantially reduces weight loss efficacy
10.1172/JCI97233 3
Phase 3: Huge studies come next, comparing the new drug to existing options to gather the evidence needed for FDA review
S., Minaai, M., Li, S., Gaudino, G., Pass, H
While small molecules like nicotine or estrogen can be absorbed via a patch, GLP-1 molecules are roughly ten times larger than the limit for skin absorption
